First-pass extracted concept

CRISPR/Cas9-mediated genome editing targeting the BCL11A enhancer

Candidate: concept label1 source documents3 linked claims

Jump to evidence Jump to sources Jump to claims

Live refresh every 5sNext refresh in 5s

Evidence Snippets

Gene therapy approaches, including ... CRISPR/Cas9-mediated genome editing targeting the BCL11A enhancer, have shown promising results in clinical trials and have gained regulatory approval in several regions.

Evidence 1Source 1DOI PubMedprovenance

Supporting Sources

Source 1primary paper2025MEDDOI PubMed

1 evidence snippet 3 linked claims Claim 1 Claim 2 Claim 3

Linked Claims

Claim 1therapeutic statussupports2025Source 1DOI PubMed

CRISPR/Cas9-mediated genome editing targeting the BCL11A enhancer has shown promising results in clinical trials and has gained regulatory approval in several regions for β-thalassemia.

Claim 2treatment limitationsupports2025Source 1DOI PubMed

Allogeneic hematopoietic stem cell transplantation for β-thalassemia is limited by donor constraints and procedure-related complications.

Claim 3treatment limitationsupports2025Source 1DOI PubMed

Regular blood transfusions, iron chelation, and supportive care in β-thalassemia remain palliative despite improving patient survival.